The Patient's Guide to Adjusting Antidepressant Dose Without Losing Continuity

Most antidepressants are not prescribed at the dose that will ultimately produce the best result for you. They are prescribed at a lower dose, intentionally, to give your body time to adapt before the medication reaches its therapeutic level. This is not a failure of prescribing. It is the standard clinical approach, and it works: slower titration means fewer people stop because of overwhelming early side effects.

But it also means that for many patients, the question is not just “is this medication working” but “have I actually been on a real trial of this medication at a dose that gives it a chance.” The starting dose and the therapeutic dose are often not the same.

This is why dose adjustment is not an emergency signal. It is a normal, expected part of antidepressant treatment. What makes the difference between a dose adjustment that works and one that does not is the clinical picture behind it.

Why Your Starting Dose Is Probably Not Your Therapeutic Dose

The “start low and go slow” principle in antidepressant prescribing serves a specific clinical purpose: it reduces the intensity of early side effects, which are the primary driver of dropout in the first weeks of treatment. A patient who starts sertraline at 25mg instead of 50mg is less likely to experience intolerable nausea or activation in week one and more likely to stay in treatment long enough to reach the dose that works.

But the starting dose is explicitly not intended to be the final dose. APA practice guidelines specify that the initial dose should be raised incrementally as tolerated until a therapeutic dose is reached or the patient achieves remission, and that titration can generally be accomplished over the initial weeks. The therapeutic dose ranges for common antidepressants extend well above their starting doses:

• Sertraline: starting 50mg, therapeutic range 50 to 200mg

• Escitalopram: starting 10mg, therapeutic range 10 to 20mg (lower ceiling than most)

• Fluoxetine: starting 10 to 20mg, therapeutic range 20 to 60mg

• Duloxetine: starting 20 to 30mg, therapeutic range 60 to 120mg

• Bupropion XL: starting 150mg, therapeutic range 150 to 450mg

Many patients experience only a partial response at their starting or first-titration dose. This is not medication failure. It is the expected outcome at a dose that has not yet reached the therapeutic threshold for that individual.

The Standard Titration Timeline

Clinical guidelines from multiple sources converge on 4-week assessment intervals as the standard for antidepressant monitoring. Evidence-based recommendations state that when using a single antidepressant from treatment initiation, something clinically important should happen at 2-week intervals: at week 2, if there is no clinically detectable improvement and the medication is well tolerated, the dose should be increased. At week 4, if there is no 50% improvement, the dose could be increased further or a switch considered.

The VA/DoD and CANMAT 2023 guidelines both align on this framework. VA clinical guidance specifies that a 25% or greater reduction in baseline PHQ-9 score by week 6 indicates a patient may benefit from an increase in dose if tolerated. Below 25% improvement at week 6 at an adequate dose is a signal to reassess the treatment strategy.

This timeline has a practical implication: the decision to increase a dose, or to switch to a different medication, should be data-driven and calibrated against a measurable response signal. Not against the feeling of the last appointment conversation.

What to Expect When Your Dose Changes

Each dose increase temporarily resets some of the adaptation that reduced your initial side effects. When you increase from 50mg to 100mg sertraline, or from 10mg to 20mg escitalopram, your body is encountering a new level of serotonergic activity. The nausea, insomnia, or mild activation you experienced at the start may return at a lower intensity for 1 to 2 weeks before subsiding.

This is expected and not a sign that the new dose is wrong for you. The same physiological process that caused the initial side effects is happening at a smaller scale with each incremental increase. Most patients find that the recurrence at dose increases is milder than the initial side effects and resolves faster.

What to monitor after a dose increase:

• Any recurrence of nausea, insomnia, or activation (expect resolution within 2 weeks)

• Sleep quality at the new dose (some medications are more activating at higher doses and may benefit from morning dosing)

• Mood and energy trajectory as the new dose stabilizes

• Any new side effects not experienced at the lower dose

Contact your prescriber if side effects from a dose increase are severe, are worsening beyond 2 weeks, or include any symptoms of serotonin syndrome: fever, rapid heart rate, muscle rigidity, or extreme agitation. Call 911 if these symptoms are severe.

The Data Problem in Dose Adjustment

The quality of a dose adjustment decision depends entirely on the quality of the data behind it. A prescriber at a quarterly appointment is making a decision about whether to increase, maintain, or change your dose based on what you can remember and accurately report about the previous 90 days.

This creates a specific problem: research on antidepressant adherence found that approximately 60% of patients discontinue within three months, with many stopping in the early weeks when side effects are most prominent. But even among patients who stay on the medication, the adherence may not have been consistent. A patient who missed doses 3 to 4 times a week during month two has effectively had a much lower average dose than prescribed. This looks like non-response. It may actually be under-exposure.

A prescriber who knows what the adherence pattern was, what side effects emerged and when they resolved, and what the symptom trajectory looked like week by week is making a fundamentally different decision. The data is not just useful context. It is the difference between a dose increase that is appropriate and one that is not needed at all.

When a Dose Increase May Not Be the Right Move

Not every partial response at 6 to 8 weeks warrants a dose increase. Several factors argue against increasing dose and in favor of alternatives:

The current dose is already at the maximum or near maximum. For escitalopram, the maximum dose is 20mg. Increasing beyond this is not supported and carries additional side effect risk. Higher doses of SSRIs do not reliably produce proportionally better outcomes.

Adherence was not consistent. If dose adherence was irregular, the first intervention is a structured adherence approach, not an increase. Inconsistent dosing of an SSRI can itself produce a pattern that looks like partial response.

The partial response came with significant side effects at the current dose. If increasing the dose is likely to intensify side effects that are already impairing quality of life, switching to a different medication with a better tolerability profile is a more appropriate next step.

There are comorbid conditions that need to be addressed. Active alcohol use, untreated thyroid dysfunction, chronic sleep disruption, and unaddressed life stressors can all cap treatment response regardless of dose. Addressing these may produce better results than a dose increase alone.

When Switching Is the Right Call

Switching antidepressants, when it is the right clinical call, requires a process called cross-tapering: gradually reducing the current medication while introducing the new one, to avoid discontinuation symptoms and allow the new medication to establish therapeutic levels. Clinical guidelines recommend cross-tapering as the preferred method of switching antidepressants in most cases, typically over 2 to 4 weeks.

Switching abruptly, which is sometimes what happens when patients stop on their own and restart a new prescription, risks both discontinuation syndrome from the old medication and under-dosing of the new one. The clinical management of a switch is more complex than it appears on paper and requires prescriber oversight at each step.

Do not switch, reduce, or stop your antidepressant without guidance from your prescriber. If you feel your current medication is not right for you, that clinical assessment and any resulting change should happen within a supervised care relationship, not unilaterally.

How SiggyMD Approaches Titration

SiggyMD’s daily check-in data gives prescribers the information needed to make evidence-based titration decisions at the right intervals. The prescriber reviewing a dose increase does not wait for a scheduled appointment to see what happened. They see the adherence patterns, the side effect trajectory at the current dose, and the symptom movement in real time.

When a dose change is made, the daily check-in continues to capture what happens next: whether the expected side effect recurrence occurred and resolved, whether the new dose level is producing the symptom movement the prescriber was looking for, and whether any unexpected effects warrant an earlier follow-up. The titration is not a one-time decision. It is a monitored process.

“Dose decisions should be made on data, not on guesswork about what has been happening for three months,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “When I increase a dose, I want to see the adherence, the side effect timeline, and the symptom trajectory from the past four weeks. That tells me whether the increase is warranted and what I should be looking for over the next two weeks to confirm it is working. Without that data, I’m making a decision in the dark.”

What Members Are Saying

PL

P.L., 38

Major Depressive Disorder

“I had been told I needed a higher dose but I was nervous about side effects. My prescriber showed me my daily data: adherence was actually inconsistent for the past month. She suggested we focus on consistency first before increasing. Three weeks later, at the same dose, I was significantly better. I didn’t need a higher dose. I needed to actually take the dose I was on.”

AM

A.M., 51

Generalized Anxiety Disorder

“When my dose was increased, the nausea came back and I panicked that something was wrong. My prescriber had already told me this was likely to happen and to log it. I logged it every day and saw it decline over 10 days. Having the data showed me I was on a normal trajectory. Without that context, I would have stopped.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. SiggyMD is currently invite-only.

Bottom Line

Dose adjustment is not an emergency. It is a normal part of antidepressant treatment. The starting dose is designed to minimize early side effects, not to produce the full therapeutic response. For many patients, reaching the therapeutic threshold means titration over the first several weeks of treatment.

What makes that titration process work is continuity: a prescriber who knows what has happened at each dose level, what the adherence was, what side effects emerged and resolved, and what the symptom trajectory looks like. That information exists in daily monitoring data. In quarterly appointment conversations, it mostly does not exist at all. The dose adjustment that is right for you depends on the clinical picture behind it.

Sources

• American Psychiatric Association. Treating Major Depressive Disorder: A Quick Reference Guide. APA Practice Guidelines. Accessed June 2026.

• Blier P. Optimal use of antidepressants: When to act? Journal of Psychiatry and Neuroscience. 2009;34(1):E1-E2.

• U.S. Department of Veterans Affairs. Clinical Pearls for Depression Management in Primary Care. VA PBM Academic Detailing. 2020.

• Shrivastava A, et al. Clinical Practice Guidelines for the management of Depression. Indian Journal of Psychiatry. 2017;59(Suppl 1):S34-S50.

• Rossom RC, et al. Antidepressant Adherence Across Diverse Populations and Healthcare Settings. Depression and Anxiety. 2016;33(8):765-774.

• Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: Validity of a Brief Depression Severity Measure. Journal of General Internal Medicine. 2001;16(9):606-613.

• American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder. APA. Accessed June 2026.